News Sentiment

CTKB sentiment intelligence

Cytek Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 4.62 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+0.7% over one week, +16.7% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Cytek Biosciences (Nasdaq: CTKB) sets severance and consulting terms

Market Reaction

Balanced read

50/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction 0.7% Price digesting
Trend fit Trend inactive 16.7% over four weeks
Fair value -14.8% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 7
Neutral 49
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
TradingView 12
Stock Titan 11
GlobeNewswire 4
MT Newswires 2
The Globe and Mail 2
www.marketscreener.com 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 25
Analyst action 4
Macro sensitivity 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 60
Stock Titan Direct company coverage

Cytek Biosciences (CTKB) CTO Yan Ming reports bona fide gift of shares

Cytek Biosciences' Chief Technology Officer, Yan Ming, reported a bona fide gift of 135,892 shares of common stock. This transaction, indicated by a Form 4 filing, involved no monetary exchange ($0.00 price per share) and was a non-market transfer. Following the gift, Ming retain

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 07:10
Source
Stock Titan
TradingKey Direct company coverage

Cytek Biosciences Inc (CTKB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Cytek Biosciences Inc (CTKB) as of FY2023. It categorizes revenue by business segments, showing that Biotechnology, pharmaceutical, distributor, and CRO contributed 57.93% and Academia and government contributed 42.07%. The r

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 04:40
Source
TradingKey
Investing.com Direct company coverage

Cytek Biosciences shareholders elect directors and approve key proposals at annual meeting

Cytek Biosciences (NASDAQ:CTKB) held its 2026 annual meeting where shareholders elected three Class II directors, approved executive compensation, and ratified Deloitte & Touche LLP as the independent auditor. The company, with a market cap of $526.9 million, is considered underv

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 03:10
Source
Investing.com
Stock Titan Direct company coverage

Cytek Biosciences (CTKB) details 2026 shareholder meeting voting outcomes

Cytek Biosciences (CTKB) reported the outcomes of its 2026 annual shareholder meeting held on June 10, 2026. A strong quorum of approximately 86.1% of eligible shares was established. Shareholders approved three director nominees and two additional proposals with significant "for

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 20:10
Source
Stock Titan